AstraZeneca PLC (AZNCF)
AZNCF Stock Price Chart
Explore AstraZeneca PLC interactive price chart. Choose custom timeframes to analyze AZNCF price movements and trends.
AZNCF Company Profile
Discover essential business fundamentals and corporate details for AstraZeneca PLC (AZNCF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - General
IPO Date
13 Feb 2009
Employees
94.30K
Website
https://www.astrazeneca.comCEO
Pascal Claude Roland Soriot
Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
AZNCF Financial Timeline
Browse a chronological timeline of AstraZeneca PLC corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 27 Apr 2026
Upcoming earnings on 4 Feb 2026
Upcoming earnings on 6 Nov 2025
Earnings released on 29 Jul 2025
EPS came in at $1.57 falling short of the estimated $2.15 by -26.98%, while revenue for the quarter reached $14.46B , missing expectations by -1.99%.
Earnings released on 29 Apr 2025
EPS came in at $1.92 falling short of the estimated $2.23 by -13.90%, while revenue for the quarter reached $13.59B , missing expectations by -3.34%.
Earnings released on 6 Feb 2025
EPS came in at $0.96 falling short of the estimated $2.07 by -53.62%, while revenue for the quarter reached $14.89B , beating expectations by +11.60%.
Dividend declared on 6 Feb 2025
A dividend of $1.03 per share was announced, adjusted to $1.03. The dividend will be paid on 8 Sept 2025.
Dividend declared on 6 Feb 2025
A dividend of $2.10 per share was announced, adjusted to $2.12. The dividend was paid on 24 Mar 2025.
Earnings released on 12 Nov 2024
EPS came in at $0.92 falling short of the estimated $2.04 by -55.15%, while revenue for the quarter reached $13.57B , beating expectations by +3.74%.
Earnings released on 25 Jul 2024
EPS came in at $1.24 falling short of the estimated $1.97 by -37.06%, while revenue for the quarter reached $12.96B , beating expectations by +2.69%.
Earnings released on 25 Apr 2024
EPS came in at $1.40 falling short of the estimated $1.91 by -26.70%, while revenue for the quarter reached $12.62B , beating expectations by +6.99%.
Earnings released on 7 Mar 2024
EPS came in at $0.62 falling short of the estimated $1.46 by -57.88%, while revenue for the quarter reached $12.34B , beating expectations by +2.14%.
Dividend declared on 21 Feb 2024
A dividend of $1.00 per share was announced, adjusted to $0.99. The dividend was paid on 9 Sept 2024.
Dividend declared on 8 Feb 2024
A dividend of $1.97 per share was announced, adjusted to $1.97. The dividend was paid on 25 Mar 2024.
Earnings released on 9 Nov 2023
EPS came in at $0.88 falling short of the estimated $1.69 by -47.87%, while revenue for the quarter reached $11.49B , missing expectations by -0.52%.
Earnings released on 30 Jun 2023
EPS came in at $1.17 falling short of the estimated $1.98 by -40.91%, while revenue for the quarter reached $11.42B , beating expectations by +3.67%.
Earnings released on 31 Mar 2023
EPS came in at $1.16 falling short of the estimated $1.71 by -32.16%, while revenue for the quarter reached $10.88B , beating expectations by +2.59%.
Earnings released on 9 Feb 2023
EPS came in at $1.38 surpassing the estimated $1.34 by +2.99%, while revenue for the quarter reached $11.21B , missing expectations by -0.38%.
Dividend declared on 9 Feb 2023
A dividend of $0.93 per share was announced, adjusted to $0.91. The dividend was paid on 11 Sept 2023.
Dividend declared on 9 Feb 2023
A dividend of $1.97 per share was announced, adjusted to $1.96. The dividend was paid on 27 Mar 2023.
Earnings released on 10 Nov 2022
EPS came in at $1.67 surpassing the estimated $1.53 by +9.15%, while revenue for the quarter reached $10.98B , beating expectations by +1.79%.
Earnings released on 29 Jul 2022
EPS came in at $1.72 surpassing the estimated $1.57 by +9.55%, while revenue for the quarter reached $10.77B , beating expectations by +3.03%.
Earnings released on 29 Apr 2022
EPS came in at $1.89 surpassing the estimated $1.71 by +10.53%, while revenue for the quarter reached $11.39B , beating expectations by +5.34%.
Earnings released on 10 Feb 2022
EPS came in at $1.67 surpassing the estimated $1.55 by +7.74%, while revenue for the quarter reached $12.01B , beating expectations by +8.11%.
Dividend declared on 10 Feb 2022
A dividend of $0.93 per share was announced, adjusted to $0.93. The dividend was paid on 12 Sept 2022.
Dividend declared on 10 Feb 2022
A dividend of $1.97 per share was announced, adjusted to $1.97. The dividend was paid on 28 Mar 2022.
Earnings released on 12 Nov 2021
EPS came in at $1.08 falling short of the estimated $1.28 by -15.62%, while revenue for the quarter reached $9.87B .
Earnings released on 29 Jul 2021
EPS came in at $0.90 falling short of the estimated $0.91 by -1.10%, while revenue for the quarter reached $8.22B .
Earnings released on 30 Apr 2021
EPS came in at $1.63 surpassing the estimated $1.49 by +9.40%, while revenue for the quarter reached $7.32B .
Earnings released on 11 Feb 2021
EPS came in at $1.07 falling short of the estimated $1.24 by -13.71%, while revenue for the quarter reached $7.41B .
Dividend declared on 11 Feb 2021
A dividend of $0.90 per share was announced, adjusted to $0.90. The dividend was paid on 13 Sept 2021.
Earnings released on 5 Nov 2020
EPS came in at $0.94 falling short of the estimated $0.95 by -1.05%, while revenue for the quarter reached $6.58B .
Dividend declared on 5 Nov 2020
A dividend of $1.90 per share was announced, adjusted to $1.94. The dividend was paid on 29 Mar 2021.
AZNCF Stock Performance
Access detailed AZNCF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.